Publication | Closed Access

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

Advanced NsclcOncologyMetronomic TherapyClinical TrialsPharmacotherapyCancer TreatmentMedicineRadiation OncologyMolecular OncologyEortc 08021/IlcpHealth Sciences